🆙 #ASCO26 #LCSM Oral Abstract Session 🔥 WU-KONG28: Sunvozertinib Mono vs Platinum-Based Chemo as 1L Tx for Advanced NSCLC with EGFR Exon20ins 🎤 Dr. John V. Heymach 📋 LBA8500 / NCT05668988 🔗 www.asco.org/abstracts-pr... @oncoalert.bsky.social @ascocancer.bsky.social @iaslc.bsky.social

🆙 #ASCO26 #LCSM Oral 🔥 Upfront vs Delayed Cranial RT in Asymptomatic BM of EGFR+, ALK+ NSCLC ✅ 2y ICP: 21.7% vs 50% ✅ OS: 23.3 vs 28.7m (No diff) 🎤 Dr. Anil Ramakant Tibdewal 📋 Abst.8624 / NCT05236946 🔗 www.asco.org/abstracts-pr... @oncoalert.bsky.social @ascocancer.bsky.social @iaslc.bsky.social

🆙 #ASCO26 #LCSM Oral 🔥CHRYSALIS-2: 1L Ami-Laz in Atypical EGFR-Mutated Advanced NSCLC ✅mOS 41.0m ✅3-yr OS 55%, 4-yr OS 46% ✅20% still on 1L tx (up to 4.4yr) 🎤Dr. Joel W. Neal 📋8501 / NCT04077463 🔗 www.asco.org/abstracts-pr... @oncoalert.bsky.social @ascocancer.bsky.social @iaslc.bsky.social

🔥BREAKING‼️ @nejm.bsky.social 🆙 ✅WU-KONG28: Sunvozertinib vs Platinum-CT as 1st-Line Tx for Advanced NSCLC with EGFR Exon20ins 🎯ORR 58.9 vs 31.1% 🎯PFS HR 0.65 (95%CI 0.50-0.85) 🎯1-y PFS rate 46.1 vs. 26.7% 🎙️ Dr. Caicun Zhou 🔜 #ASCO26 #LCMS, ORAL @oncoalert.bsky.social

🔥ASCO Living Guideline update: Stage IV NSCLC with driver alterations 2026.3.1 🆙 Journal of Clinical Oncology ☑Latest update incorporating new evidence for targeted therapies 🎙Dr. Joshua Reuss / Dr. Sonam Puri #LCSM @oncoalert.bsky.social @ascocancer.bsky.social

🔥ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1 🆙 @JCO_ASCO ☑Latest update incorporating new evidence for ICI-based regimens in NSCLC 🎙Dr. Lyudmila Bazhenova @hhorinouchi.bsky.social #LCSM @oncoalert.bsky.social @ascocancer.bsky.social doi.org/10.1200/JCO-...

🚨 We are @Oncoalert 🔝 #ASCO26 coverage by 💯 faculties @oncoalert.bsky.social @ascocancer.bsky.social

🆙 #ASCO26 #LCSM OncoAlert🔝🔟 1 HARMONi-6 2 LIBRETTO-432 3 WU-KONG28 4 OptiTROP-Lung05 5 TRITON and more Leads: @hhorinouchi.bsky.social Dr. Uğur Özkerim Dr. Gil Morgan @oncoalert.bsky.social @ascocancer.bsky.social

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 2 ☑️YL202/BNT326: HER3 ADC 🎯ORR across doses: 22.7-55.6% 🎯mPFS across doses: 2.8-10.0m 🎙️Dr. Haifeng Liu 🎙️Chair: Dr. Kersti Oselin, Dr. Mariano Provencio Pulla 📍NCT06107686 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 2 ☑️SHR-A2009: HER3 ADC + aumolertinib 🎯ORR ≥2L/1L: 43.8-51.7%/77.4-66.7% 🎯mPFS ≥2L/1L: 8.1m/14.4m 🎙️Prof. Yi-Long Wu 🎙️Chair: Dr. Kersti Oselin, Dr. Mariano Provencio Pulla 📍NCT06092268 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 2 ☑️TQB2922: EGFR/c-MET bispecific antibody +/- bev 🎯ORR mono vs. combi: 21.2%/64.7% 🎯Monotherapy TRAEs: rash 61.3%, IRR 50.7% 🎙️Dr. Jinhui Xue 🎙️Chair: Dr. Kersti Oselin, Dr. Mariano Provencio Pulla 📍NCT06188624 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 2 ☑️Blueprint AI: AI-assisted PD-L1 scoring 🎯AI was non-inferior to standard pathologists across all clones 🎙️Dr. Fred Hirsch 🎙️Chair: Dr. Kersti Oselin, Dr. Mariano Provencio Pulla 📍NA @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 2 ☑️Tripalimab: Subcutaneous vs. IV 🎯Noninferiority of exposure of SC to IV tripalimab 🎙️Dr. Lin Wu 🎙️Chair: Dr. Kersti Oselin Dr. Mariano Provencio Pulla 📍NCT06505837 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 2 ☑️KEYNOTE-671: 5 years F/U in pCR subgroup 🎯EFS HR 0.37, 5-y rate 80.8% vs. 55.7% 🎙️Dr. Margarita Majem 🎙️Chair: Dr. Kersti Oselin, Dr. Mariano Provencio Pulla 📍NCT03425643 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 2 ☑️KEYNOTE-671: 5 years F/U in non-pCR subgroup 🎯EFS HR 0.69, 5-y rate 42.9% vs. 25.2%, OS immature 🎙️Dr. Martin Reck 🎙️Chair: Dr. Kersti Oselin, Dr. Mariano Provencio Pulla 📍NCT03425643 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 1 ☑️KANDLELIT-001: MK-1084 + Pembrolizumab in KRAS G12C 🎯Tx Naive mNSCLC (PD-L1 ≥50%): ORR 92%, mPFS 29m 🎙️Dr. Adrian G. Sacher 🎙️Chair: Dr. Adrian Sacher Dr. Andreas Rimner 📍NCT05067283 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 1 ☑️BECOME: Becotarug + Osimertinib in EGFR ex20ins 🎯Helical ins: ORR 77.8% 🎯Near/Far loop ins: ORR 46.9%/48.7% 🎙️Dr. Jinhui Xue 🎙️Chair: Dr. Adrian Sacher Dr. Andreas Rimner 📍NCT05132777 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 1 ☑️Beamion LUNG-1: Zongertinib in 1st line 🎯ORR 76%, DOR 15.2m, mPFS 14.4m 🎯RANO-BM ORR: 47% 🎙️Dr. John Heymach 🎙️Chair: Dr. Adrian Sacher, Dr. Andreas Rimner 📍NCT04886804 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 1 ☑️ASTEROID: SBRT +/- Durvalumab 🎯Time to progression was significantly improved by durvalumab 🎙️Dr. Andreas Hallqvist 🎙️Chair: Dr. Adrian Sacher, Dr. Andreas Rimner 📍NCT03446547 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 1 ☑️ETOP ADEPPT: Adagrasib in elderly or poor PS pts with KRAS G12C 🎯Elderly + PS 0-1: cORR 31%, mPFS 7.6m 🎯PS2: cORR 18%, mPFS 2.7m 🎙️ @drjnaidoo.bsky.social 🎙️Chair: Dr. Adrian Sacher Dr. Andreas Rimner 📍NCT05673187 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 1 ☑️KANDLELIT-001: MK-1084 + Pembrolizumab in KRAS G12C 🎯Tx Naive mNSCLC (PD-L1 ≥50%): ORR 92%, mPFS 29m 🎙️Dr. Adrian G. Sacher 🎙️Chair: Dr. Adrian Sacher, Dr. Andreas Rimner 📍NCT05067283 @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Integrating new drug in early stage disease ☑️ #TKI #Immunotherapy #Radiotherapy #Surgery 🎙️Chair: Dr. Patrick Forde Dr. Laura Mezquita @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Unlocking the future: Bispecific immunotherapy and novel combinations in lung cancer ☑️ #ADC #SCLC #Toxicity #Biomarker 🎙️Chair: Dr. Jhanelle Gray, Dr. Benjamin Besse @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Proffered Paper session 1 ☑️Obrixtamig + ezabenlimab in SCLC or NECs 🎯Overall: ORR 30%, DCR 58%, mPFS 4.4m 🎯Highest dose: ORR 58%, DCR 83%, mPFS 10m 🎙️ Dr. Julien Mazieres 🎙️Chair: @solangepeters.bsky.social 📍NCT05879978 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Proffered Paper session 1 ☑️iza-bren (BL-B01D1) + serplulimab in SCLC 🎯ORR 88.3%, mPFS 8.2m, 12m OS rate 80.8% 🎙️Dr. Fei Zhou 🎙️Chair: @solangepeters.bsky.social 📍NCT06437509 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Proffered Paper session 1 ☑️Setidegrasib in KRAS G12D 🎯ORR 35.6%, mPFS 8.3m 🎙️Dr. Philippe CASSIER 🎙️Chair: @solangepeters.bsky.social 📍NCT05382559 @oncoalert.bsky.social LARVOL #LCSM

🆙 #ELCC26 @myesmo.bsky.social 🔥Proffered Paper session 1 ☑️TOP study: Osimertinib +/- Chemo in EGFRm + TP53 mutation 🎯PFS HR 0.44 (95%CI 0.32-0.61), ORR 82.9% vs. 72.0% 🎙️Dr. Yunpeng Yang 🎙️Chair: @solangepeters.bsky.social 📍NCT04695925 @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Perioperative treatments for early lung cancer ☑️ #AGA #Adjuvant #Neoadjuvant #Perioperative #Biomarker 🎙️Chair: Dr. Enriqueta Felip, Dr. James Spicer @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥From science to clinic: Understanding resistance to targeted therapies ☑️ #Immunotherapy #TKIresistance #SCLC 🎙️Chair: Dr. Chiara Ambrogio Dr. Xiuning Le @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥T-cell engagers: A new class of drugs (ETOP IBCSG) ☑️ #SCLC #NSCLC #Metothelioma #Toxicities #CART 🎙️Chair: Dr. Luis Paz-Ares @solangepeters.bsky.social @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Adaptive escalation and de-escalation treatment for NSCLC ☑️ #Biomarker #DeEscalation #Escalation #TrialDesign 🎙️Chair: Dr. Stephanie Saw Dr. Jordi Remon @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥ctDNA integration in clinical practice ☑️ #MRD #Advancedstage #Timing 🎙️Chair: Dr. Umberto Malapelle Dr. Mihaela Aldea @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 2 ☑️KN-671: Non-pCR and pCR ☑️SubQ Toripalimab ☑️PDL1 Blueprint AI ☑️OptiTROP-Lung03 ☑️TQB2922: EGFR/MET bispecifc ☑️SHR-A2009: HER3 ADC ☑️BNT326: HER3 ADC 🎙️Chair: Dr. Kersti Oselin Dr. Mariano Provencio Pulla @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Neoadjuvant vs perioperative in stage II NSCLC: Just to keep things confusing ☑️ #Neoadjuvant vs. #Perioperative 🎙️Chair: Dr. Mariano Provencio Pulla @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Mini Oral session 1 ☑️KANDLELIT-001: MK-1084 + Pembro ☑️ETOP ADEPPT: Adagrasib ☑️NorthStar ☑️ASTEROID: SBRT -> Durvalumab ☑️Beamion LUNG-1 ☑️BECOME: Becotarug + Osi in EGFR ex20ins 🎙️Chair: Dr. Adrian Sacher Dr. Andreas Rimner @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Defining the limits of surgery in lung cancer ☑️ #Segmentectomy #StageIII #Resectability 🎙️Chair: Dr. Isabelle Opitz, Dr. Kenji Suzuki @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥The evolving role of ADCs in thoracic malignancies ☑️ #Structure #Combination #Resistance #NovelADCs 🎙️Chair: Dr. Hye Ryun Kim, Dr. Pasi A. Jänne @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥EGFR-mutant NSCLC across the disease spectrum: From cure to control ☑️ #Resectable #LocallyAdvanced #Advanced #Resistance 🎙️Chair: Dr. Myung-Ju Ahn @antoniopassaro.bsky.social @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Don’t miss the target: BRAF, HER2, METex14 and EGFR exon20 in focus ☑️ #BRAF #HER2 #METex14 #EGFRex20ins 🎙️Chair: Dr. Caicun Zhou, Dr. Natasha Leighl @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥New horizons in therapeutic targets for thoracic malignancies ☑️ #SMARCA4 #MTAP #Bispecific #Trispecific #ADC 🎙️Chair: Dr. Keith M. Kerr, Dr. Junko Tanizaki @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Special scenarios: The role of local therapy in metastatic disease ☑️ #Oligomets #Radiotherapy #Surgery 🎙️Chair: Dr. Natasha Leighl Dr. Miguel García Pardo de Santayana @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Predictive immunohistochemistry for ADCs ☑️ #HER2 #MET #DigitalPathology #AI 🎙️Chair: Dr. Fernando Lopez-Rios, Dr. Umberto Malapelle @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥YO Vesalius session - Finding your niche in thoracic oncology 🎙️Dr. Stephanie Saw 🎙️Chair: Dr. Hongcheng Zhu, Dr. Myrto Moutafi @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Progress in targeting KRAS in lung cancer ☑️#KRAS #G12C #PanRAS #CellTherapy #Resistance 🎙️Chair: @bensolomon1.bsky.social @drjnaidoo.bsky.social @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Redrawing the lines: Rethinking resectability in stage IIIB NSCLC ☑️Cutting through the dogma 🎙️ Dr. Brendon Stiles ☑️Balancing evidence and excision 🎙️Dr. Clara Chan 🎙️Chair: @drjnaidoo.bsky.social @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Proffered Paper session 1 ☑️Setidegrasib in KRAS G12D ☑️TOP study: Osimertinib +/- Chemo in EGFRm + TP53m ☑️iza-bren + serplulimab in SCLC ☑️Obrixtamig + ezabenlimab in DLL3+ SCLC 🎙️Chair: @solangepeters.bsky.social @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Updates on management of fusion-positive NSCLC ☑️ #AlK #ROS1 #RET #NTRK 🎙️Chairs: Dr. Alex Drilon, Dr. Thomas Stinchcombe @oncoalert.bsky.social LARVOL #LCSM

🔜 #ELCC26 @myesmo.bsky.social 🔥Keynote lecture 1 ☑️The future of biomarkers in the ADC era 🎙️ Dr. Fred Hirsch @oncoalert.bsky.social LARVOL #LCSM

🔥Oncology HERE & NOW Webcast/Podcast🆙 🚨 @realbowtiedoc.bsky.social & @crisbergerot.bsky.social 🎯 #SupportiveCare , the future of #Telemedicine ✅Japanese🇯🇵captions are available in #Youtube youtu.be/4WYdTostU7w?... @oncoalert.bsky.social buzzsprout.com/1324033/epis...

⏰NOW OUT‼️#ELCC25 🔥COCOON🦋: Preventing Moderate to Severe Dermatologic Adverse Events in 1st-line EGFR-mutant Advanced NSCLC Treated with Amivantamab + Lazertinib 🎙️ Dr. Nicolas Girard 🎯AEs ≥G2: OR 0.19 (95%CI, 0.09–0.40) ✅NCT06120140 #LCSM @oncoalert.bsky.social @myesmo.bsky.social @iaslc.bsky.social